{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:22:31Z","timestamp":1790400151105,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673004, 81372245"],"award-info":[{"award-number":["81673004, 81372245"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antiangiogenic agents are commonly used in lung and colon cancer treatments, however, rapid development of drug resistance limits their efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Lentinan (LNT) is a biologically active compound extracted from <jats:italic>Lentinus edodes<\/jats:italic>. The effects of LNT on tumor angiogenesis were evaluated by immunohistochemistry in murine LAP0297 lung and CT26 colorectal tumor models. The impacts of LNT on immune cells and gene expression in tumor tissues were determined by flow cytometry, qPCR, and ELISA. Nude mice and IFN\u03b3 blockade were used to investigate the mechanism of LNT affecting on tumor angiogenesis. The data sets were compared using two-tailed student\u2019s <jats:italic>t<\/jats:italic> tests or ANOVA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that LNT inhibited tumor angiogenesis and the growth of lung and colon cancers. LNT treatments elevated the expression of angiostatic factors such as IFN\u03b3 and also increased tumor infiltration of IFN\u03b3-expressing T cells and myeloid cells. Interestingly, IFN\u03b3 blockade, but not T cell deficiency, reversed the effects of LNT treatments on tumor blood vessels. Moreover, long-lasting LNT administration persistently suppressed tumor angiogenesis and inhibited tumor growth.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LNT inhibits tumor angiogenesis by increasing IFN\u03b3 production and in a T cell-independent manner. Our findings suggest that LNT could be developed as a new antiangiogenic agent for long-term treatment of lung and colon cancers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-018-0932-y","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T14:36:13Z","timestamp":1540823773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Lentinan inhibits tumor angiogenesis via interferon \u03b3 and in a T cell independent manner"],"prefix":"10.1186","volume":"37","author":[{"given":"Shengming","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Kuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"932_CR1","first-page":"193","volume":"1855","author":"Y Huang","year":"2015","unstructured":"Huang Y, Carbone DP. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. Biochim Biophys Acta. 2015;1855:193\u2013201.","journal-title":"Biochim Biophys Acta"},{"key":"932_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"932_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298\u2013307.","journal-title":"Nature"},{"key":"932_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542\u201350.","journal-title":"N Engl J Med"},{"key":"932_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182\u20136.","journal-title":"N Engl J Med"},{"key":"932_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2016.12.009","volume":"31","author":"JS Park","year":"2017","unstructured":"Park JS, Kim IK, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo DC, He Y, Augustin HG, Kim I, Lee D, Koh GY. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2017;31:157\u20138.","journal-title":"Cancer Cell"},{"key":"932_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrd2871","volume":"8","author":"PA Janne","year":"2009","unstructured":"Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009;8:709\u201323.","journal-title":"Nat Rev Drug Discov"},{"key":"932_CR8","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.4049\/jimmunol.166.4.2276","volume":"166","author":"G Beatty","year":"2001","unstructured":"Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol. 2001;166:2276\u201382.","journal-title":"J Immunol"},{"key":"932_CR9","first-page":"1728","volume":"100","author":"Y Hayakawa","year":"2002","unstructured":"Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood. 2002;100:1728\u201333.","journal-title":"Blood"},{"key":"932_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature22311","volume":"545","author":"T Kammertoens","year":"2017","unstructured":"Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, H\u00fcbner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T. Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature. 2017;545:98\u2013102.","journal-title":"Nature"},{"key":"932_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, Phung TL, Mani SA, Stossi F, Sreekumar A, Mancini MA, Decker WK, Zong C, Lewis MT, Zhang XH. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250\u20134.","journal-title":"Nature"},{"issue":"3","key":"932_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195\u2013203.","journal-title":"Nat Rev Immunol"},{"key":"932_CR13","first-page":"2751","volume":"17","author":"H Matsuoka","year":"1997","unstructured":"Matsuoka H, Seo Y, Wakasugi H, Saito T, Tomoda H. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 1997;17:2751\u20135.","journal-title":"Anticancer Res"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1871520611313050002","volume":"13","author":"K Ina","year":"2013","unstructured":"Ina K, Kataoka T, Ando T. The use of lentinan for treating gastric cancer. Anti Cancer Agents Med Chem. 2013;13:681\u20138.","journal-title":"Anti Cancer Agents Med Chem"},{"key":"932_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/10408398.2011.587616","volume":"54","author":"X Xu","year":"2014","unstructured":"Xu X, Yan H, Tang J, Chen J, Zhang X. Polysaccharides in Lentinus edodes: isolation, structure, immunomodulating activity and future prospective. Crit Rev Food Sci Nutr. 2014;54:474\u201387.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1039\/c2fo10279j","volume":"3","author":"L Ren","year":"2012","unstructured":"Ren L, Perera C, Hemar Y. Antitumor activity of mushroom polysaccharides: a review. Food Funct. 2012;3:1118\u201330.","journal-title":"Food Funct"},{"key":"932_CR17","first-page":"5132","volume":"44","author":"T Suga","year":"1984","unstructured":"Suga T, Shiio T, Maeda YY, Chihara G. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res. 1984;44:5132\u20137.","journal-title":"Cancer Res"},{"key":"932_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.intimp.2009.01.010","volume":"9","author":"LD Zhou","year":"2009","unstructured":"Zhou LD, Zhang QH, Zhang Y, Liu J, Cao YM. The shiitake mushroom-derived immuno-stimulant lentinan protects against murine malaria blood-stage infection by evoking adaptive immune-responses. Int Immunopharmacol. 2009;9:455\u201362.","journal-title":"Int Immunopharmacol"},{"key":"932_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.phymed.2007.11.029","volume":"15","author":"C Israilides","year":"2008","unstructured":"Israilides C, Kletsas D, Arapoglou D, Philippoussis A, Pratsinis H, Ebringerova A, Hribalova V, Harding SE. In vitro cytostatic and immunomodulatory properties of the medicinal mushroom Lentinula edodes. Phytomedicine. 2008;15:512\u20139.","journal-title":"Phytomedicine"},{"key":"932_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s005950200085","volume":"32","author":"B Sano","year":"2002","unstructured":"Sano B, Sugiyama Y, Kunieda K, Sano J, Saji S. Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model. Surg Today. 2002;32:503\u20139.","journal-title":"Surg Today"},{"key":"932_CR21","first-page":"253","volume":"58","author":"P Huang","year":"2008","unstructured":"Huang P, Duda DG, Jain RK, Fukumura D. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB\/N mice. Comp Med. 2008;58:253\u201363.","journal-title":"Comp Med"},{"key":"932_CR22","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109:17561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"932_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/01.RES.0000209968.66606.10","volume":"98","author":"RJ Bodnar","year":"2006","unstructured":"Bodnar RJ, Yates CC, Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res. 2006;98:617\u201325.","journal-title":"Circ Res"},{"key":"932_CR24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1084\/jem.20052124","volume":"203","author":"D Wang","year":"2006","unstructured":"Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203:941\u201351.","journal-title":"J Exp Med"},{"key":"932_CR25","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1158\/0008-5472.CAN-10-4366","volume":"71","author":"Y Huang","year":"2011","unstructured":"Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res. 2011;71:6122\u201331.","journal-title":"Cancer Res"},{"key":"932_CR26","first-page":"2365","volume":"32","author":"D Higashi","year":"2012","unstructured":"Higashi D, Seki K, Ishibashi Y, Egawa Y, Koga M, Sasaki T, Hirano K, Mikami K, Futami K, Maekawa T, Sudo M. The effect of lentinan combination therapy for unresectable advanced gastric cancer. Anticancer Res. 2012;32:2365\u20138.","journal-title":"Anticancer Res"},{"key":"932_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejca.2016.06.012","volume":"65","author":"S Yoshino","year":"2016","unstructured":"Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016;65:164\u201371.","journal-title":"Eur J Cancer"},{"key":"932_CR28","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943\u20138.","journal-title":"Cancer Res"},{"key":"932_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322.","journal-title":"Cancer Cell"},{"key":"932_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.18632\/oncotarget.13481","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Li W, Huang X, Liu Y, Li Q, Zheng Z, Wang K. A polysaccharide from Lentinus edodes inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice. Oncotarget. 2017;8:610\u201323.","journal-title":"Oncotarget"},{"key":"932_CR31","first-page":"2739","volume":"29","author":"K Oba","year":"2009","unstructured":"Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable\/recurrent gastric cancer. Anticancer Res. 2009;29:2739\u201345.","journal-title":"Anticancer Res"},{"key":"932_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/222687a0","volume":"222","author":"G Chihara","year":"1969","unstructured":"Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature. 1969;222:687\u20138.","journal-title":"Nature"},{"key":"932_CR33","first-page":"4015","volume":"26","author":"K Fujimoto","year":"2006","unstructured":"Fujimoto K, Tomonaga M, Goto S. A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan. Anticancer Res. 2006;26:4015\u20138.","journal-title":"Anticancer Res"},{"key":"932_CR34","first-page":"1209","volume":"32","author":"J Hamuro","year":"2005","unstructured":"Hamuro J. Anticancer immunotherapy with perorally effective lentinan. Gan To Kagaku Ryoho. 2005;32:1209\u201315.","journal-title":"Gan To Kagaku Ryoho"},{"key":"932_CR35","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.7314\/APJCP.2012.13.8.3803","volume":"13","author":"L Zhang","year":"2012","unstructured":"Zhang L, Ji Q, Ni ZH, Sun J. Prohibitin induces apoptosis in BGC823 gastric cancer cells through the mitochondrial pathway. Asian Pac J Cancer Prev. 2012;13:3803\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"key":"932_CR36","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1172\/JCI96582","volume":"128","author":"X Zheng","year":"2018","unstructured":"Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, , Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y: Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 2018, 128:2104\u20132115.","journal-title":"J Clin Invest"},{"key":"932_CR37","doi-asserted-by":"publisher","first-page":"19059","DOI":"10.1073\/pnas.1318022110","volume":"110","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013;110:19059\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"932_CR38","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/nm.3289","volume":"19","author":"KE Emblem","year":"2013","unstructured":"Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013;19:1178\u201383.","journal-title":"Nat Med"},{"key":"932_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2004.06.037","volume":"220","author":"YH Gu","year":"2005","unstructured":"Gu YH, Belury MA. Selective induction of apoptosis in murine skin carcinoma cells (CH72) by an ethanol extract of Lentinula edodes. Cancer Lett. 2005;220:21\u20138.","journal-title":"Cancer Lett"}],"updated-by":[{"DOI":"10.1186\/s13046-021-02170-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0932-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-018-0932-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0932-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T15:03:28Z","timestamp":1637766208000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0932-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0932-y","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13046-021-02170-8","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"1 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-021-02170-8","URL":"https:\/\/doi.org\/10.1186\/s13046-021-02170-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal works were approved by the Institutional Laboratory Animal Care and Use Committee of Soochow University. All of the procedures were performed in compliance with the Animal Care and Use Regulations of China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Guoxi Zhang is an employee of Nanjing Luye Pharmaceutical Co., Ltd (Nanjing, China) and provided the main research subject (Lentinan) of the study. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"260"}}